By Doug Macron

Arrowhead Research's top official last week assured investors that the company's acquisition of Alvos Therapeutics would not significantly impact its burn rate, which had already been markedly increased late last year when it acquired the RNA drug assets of Roche.

He also said that the deal is expected to give Arrowhead an edge in its longstanding effort to close a partnership with a bigger industry player, although he declined to provide any guidance on when such an arrangement might be struck.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Vivek Murthy is no longer the surgeon general of the US, the Associated Press reports.

People around the globe took to the streets to support science — some with signs.

Parents who learn of their increased genetic risk of disease also contend with telling their children about theirs, the New York Times writes.

In PLOS this week: loci linked to body mass index measurements, long non-coding RNA expression and urothelial carcinoma prognosis, and more.